ArticleDrugs - real world outcomes2022
Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Article in Drugs - real world outcomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Characterizing Ertapenem Neurotoxicity: A Systematic Review and Experience at a Tertiary Medical Center.Open forum infectious diseases · 2024Trial
- A real-world pharmacovigilance study of dacomitinib based on FDA adverse event reporting system (FAERS) database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- Safety of Fluoroquinolones and Cotrimoxazole in Urinary Tract Infections in Older Males.Open forum infectious diseases · 2026Article
- Age and Gender Heterogeneity in Adverse Drug Reactions Associated with Hemp Use: Evidence from the FDA Pharmacovigilance Data in the Last Two Decades.Drugs - real world outcomes · 2026Article
- Neuroimmune Mechanisms Transforming Acute Injury to Long-Term Brain Dysfunction After Sepsis.Clinics in chest medicine · 2026Review
- Risk of drug-related aggression in pediatric populations: a pharmacovigilance analysis using the FAERS database.Frontiers in pediatrics · 2026Article
- Anthracycline Cardiotoxicity: A Real-World Study Based on FDA Adverse Event Reporting System Database.Cardiovascular therapeutics · 2026Article
- Delirium Mistaken for Bipolar Disorder in a Paediatric Oncology Patient: A Case Report.Actas espanolas de psiquiatria · 2025Article
- Ampicillin sulbactam impacts serum potassium level comparable to piperacillin tazobactam.Scientific reports · 2025Observational
- Exploration of adverse event profiles for cefotaxime: a disproportionality analysis using the FDA adverse event reporting system.BMC pharmacology & toxicology · 2025Article
- Comment on "Drug-Induced Cognitive Impairment".Drug safety · 2025Article
- Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database.Frontiers in pharmacology · 2025Article
- Article
- The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database.PloS one · 2024Article
- A Case of Ertapenem-Induced Delirium.Cureus · 2024Article
- Amoxicillin-Induced Neurotoxicity: Contribution of a Healthcare Data Warehouse to the Determination of a Toxic Concentration Threshold.Antibiotics (Basel, Switzerland) · 2023Article
- A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.Scientific reports · 2022Article
- Postoperative Delirium in Neurosurgical Patients: Recent Insights into the Pathogenesis.Brain sciences · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundErtapenem, cefepime, imipenem, ofloxacin, ceftazidime, clarithromycin, cefaclor, levofloxacin, linezolid, moxifloxacin, azithromycin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, metronidazole, ciprofloxacin, and cefuroxime are known to be associated with delirium. Other antibiotics may also lead to delirium, but no study has systemically compared delirium associations for many available antibiotics.
objectiveThe objective of this study was to evaluate the association between delirium and antibiotics using the FDA Adverse Event Reporting System (FAERS).
methodsFAERS reports from January 1, 2004 to December 31, 2018 were included in the study. Reporting odds ratios (RORs) and corresponding 95% confidence intervals (95% CI) for the association between antibiotics and delirium were calculated. An association was considered to be statistically significant when the lower limit of the 95% CI was greater than 1.0.
resultsA total of 10,015,622 reports (including 16,982 delirium reports) were considered, after inclusion criteria were applied. Statistically significant delirium RORs (95% CI) for antibiotics were: ertapenem 21.07 (16.38-27.10), cefepime 9.8 (6.37-15.09), imipenem 9.68 (6.75-13.89), ofloxacin 7.73 (4.00-14.92), ceftazidime 6.09 (2.73-13.62), clarithromycin 5.34 (4.37-6.53), cefaclor 5.32 (1.71-16.58), ampicillin-sulbactam 4.49 (2.13-9.45), levofloxacin 4.47 (3.88-5.16), linezolid 4.33 (3.28-5.72), moxifloxacin 3.51 (2.81-4.38), azithromycin 2.76 (2.09-3.64), piperacillin-tazobactam 2.41 (1.47-3.93), trimethoprim-sulfamethoxazole 2.36 (1.61-3.47), metronidazole 1.85 (1.31-2.60), ciprofloxacin 1.83 (1.44-2.33), and cefuroxime 1.81 (1.03-3.20).
conclusionThis study found statistically significant increased risk of reporting delirium with ertapenem, cefepime, imipenem, ofloxacin, ceftazidime, clarithromycin, cefaclor, ampicillin-sulbactam, levofloxacin, linezolid, moxifloxacin, azithromycin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, metronidazole, ciprofloxacin, and cefuroxime.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.